Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.77 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.77 |
| ▸ | RELA | Q04206 | 6/20 | 0.77 |
| ▸ | NPC1 | O15118 | 11/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.67 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131467 | 0.87 | SMN1; SMN2 (1.00) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL28310352 | 0.86 | RAB9A (0.79) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL31306404 | 0.85 | GFER (0.64) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL31295460 | 0.85 | GFER (0.58) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL7570608 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL6037569 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL26373245 | 0.84 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL12258528 | 0.84 | SMN1; SMN2 (0.80) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL21446873 | 0.83 | RAB9A (0.69) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL21446750 | 0.82 | RAB9A (0.73) | RAB9ASMN1; SMN2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| CN-104447539-B | A kind of two grades, the synthetic method of three-level aromatic amides | 湖南大学 | 2017-09-15 | — | — | CN | disclosed |
| CN-104447539-A | Method for synthesizing binary and ternary aryl amide compounds | UNIV HUNAN | 2015-03-25 | — | — | CN | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885SMN1; SMN2 3410/4885NFKB1 411/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885SMN1; SMN2 3410/4885NFKB1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.